Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Small Cell Lung Cancer Recurrent × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 230 Glioma 94 Brain Neoplasms 86 Gliosarcoma 77 Astrocytoma 56 Central Nervous System Neoplasms 54 Oligodendroglioma 40 Melanoma 35 Neuroblastoma 23 Recurrence 18 Medulloblastoma 15 Ependymoma 15 Neoplasms 14 Neoplasm Metastasis 14 Sarcoma, Ewing 12 Lymphoma 10 Diffuse Intrinsic Pontine Glioma 10 Sarcoma 9 Rhabdomyosarcoma 9 Neuroendocrine Tumors 9 Lung Neoplasms 8 Unspecified Adult Solid Tumor, Protocol Specific 6 Small Cell Lung Carcinoma 5 Osteosarcoma 5 Optic Nerve Glioma 5 Neuroectodermal Tumors, Primitive 5 Colorectal Neoplasms 5 Choroid Plexus Neoplasms 5 Breast Neoplasms 5 Wilms Tumor 4

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02477813 2018-11-13

TeRes

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Terminated

Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡